Phase 2 N=51 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Brain Metastasis · Bladder Cancer · Breast Cancer
Primary: Local Control — 13; 23; 2; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=74 Sleep Disordered Breathing and Chronic Pain
Sleep Apnea Syndromes
Primary: Number of Sleep Related Events Per Hour — 38.8; 17.4; 4.5; 7.6 events/hour — p=<0.001
Phase 3 N=108 Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group
Non Alcoholic Fatty Liver Disease
Primary: Methionine Elimination Half-life Measured in Blood. — 4.29; 4.66; 4.25; 4.26 hour
Phase 1 N=28 A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage
Healthy Volunteer
Primary: Maximum Observed Plasma Concentration (Cmax) — 10.7; 9.00; 8.03; 3.97 nanograms per milliliter (ng/mL)
Phase 4 N=80 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye
Dry Eye Syndromes · Keratoconjunctivitis Sicca
Primary: Change From Baseline in Global Ocular Staining Score in the Study Eye — 5.2; 5.2; -1.5; -1.6 Scores on a Scale
N/A N=9 Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine
Cocaine Use Disorders
Primary: Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 1.00; 1.22; 5.56; 5.33 Number of Cocaine Choices
Phase 3 N=33 SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI
Atrial Fibrillation
Primary: LA Fibrosis — 24.6; 16.8 percentage of fibrosis
N/A N=12 Effects of Adding Chickpeas to the American Diet (Long Term Study)
Inflammation
Primary: Changes in Number of 16S RNA Sequences on Days 31, Day 62, and Day 93. — 49171; 48925; 49053 sequences
Phase 3 N=173 A Randomized Controlled Trial of Mandatory Naps for Physicians in Training
Fatigue
Primary: Hours Slept on Overnight Extended Duty Call Shifts — 1.98; 2.86; 2.04; 3.04 hours
Phase 3 N=1,413 Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2 · Hyperglycemia
Primary: HbA1c (Glycosylated Haemoglobin) Change From Baseline at Week 24 — -2.08; -1.93; -2.07; -1.98 percentage of HbA1c — p=0.0056
Phase 2 N=22 A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive · Lung Diseases · Respiratory Tract Diseases
Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) — 1.61; 1.58; 1.62; 1.62 Liter
N/A N=308 Adding Value in Knee Arthroplasty Post-total Knee Replacement (TKR) Care Navigator Trial
Osteoarthritis · Degenerative Joint Disease
Primary: Change in WOMAC Physical Function — -30; -27 units on a scale
N/A N=1,397 GORE Flow Reversal System and GORE Embolic Filter Extension Study
Carotid Stenosis · Constriction, Pathologic · Carotid Artery Diseases
Primary: Major Adverse Events (MAE) — 18; 36 participants
Phase 1 N=32 Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis
Renal Impairment
Primary: Number of Participants With Clinically Significant Hypocalcemia — 1; 2 participants
Phase 2 N=66 A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in Adult Attention Deficit Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale (AISRS) Total Score at Week 3 — 36.778; 38.273; 36.135…